Results 291 to 300 of about 2,173,558 (351)

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Lancet, The, 2021
Martin Hutchings, Michael Roost Clausen, Peter W M Johnson   +2 more
exaly  

The Subcutaneous Injection

AJN, American Journal of Nursing, 1971
openaire   +4 more sources

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

Lancet, The, 2023
Bruce E Strober, A David Burden, Mark G Lebwohl   +2 more
exaly  

Visualization of subcutaneous insulin injections by x-ray computed tomography

Physics in Medicine and Biology, 2012
M. Thomsen, M. Poulsen, M. Bech, A. Velroyen, J. Herzen, F. Beckmann, R. Feidenhans'l, F. Pfeiffer   +7 more
semanticscholar   +1 more source

NOTE ON THE EFFECTS PRODUCED ON MAN BY SUBCUTANEOUS INJECTIONS OF A LIQUID OBTAINED FROM THE TESTICLES OF ANIMALS.

, 1889
Brown-Séquard
semanticscholar   +1 more source

Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.

Cochrane Database of Systematic Reviews, 2010
M. Misso, Kristine J Egberts, M. Page, Denise A. O’Connor, J. Shaw   +4 more
semanticscholar   +1 more source

Subcutaneous injection

Nursing Standard, 2015
openaire   +1 more source

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis

Acta Diabetologica, 2010
M. Monami, C. Lamanna, N. Marchionni, E. Mannucci   +3 more
semanticscholar   +1 more source

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

Lancet Neurology, 2008
B. Segal, C. Constantinescu, A. Raychaudhuri, L. Kim, Rosanne Fidelus-Gort, L. Kasper   +5 more
semanticscholar   +1 more source

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Lancet, The, 2022
Simon J Bowman, Thomas Dörner, Xavier Mariette   +2 more
exaly